Recently, KansenBio announced the completion of a Pre-A financing round worth tens of millions of RMB. The round was jointly invested in by the Beijing Green Energy and Low-Carbon Industry Investment Fund, the Beijing Future Star Science and Technology Venture Capital Center, and the Beijing Changjianfa Investment Management Center under Future Science City Group. The proceeds will be used primarily to scale up the production processes and capacity of high-value product pipelines, advance international certifications and global market expansion for core raw materials, and support the development of a new generation of large-scale production lines.

Founded in 2022, KansenBio is a biomanufacturing company originating from the commercialization of core technologies developed at Tsinghua University. The company focuses on active ingredients for the health and wellness sector as well as bio-based materials. By integrating AI-driven biosynthetic pathway design, microbial strain engineering, intelligent fermentation, enzymatic conversion and product purification technologies, the company has established a synthetic biology manufacturing platform covering both R&D and industrial-scale production.

KansenBio has developed a diversified product pipeline across the nutrition, health and bio-based materials sectors, including N-acetylneuraminic acid, L-histidine, bio-based 1,3-butanediol, bio-based 1,4-butanediol and bio-based hexamethylenediamine. Its industrial demonstration platform in Changzhou, Jiangsu Province, became operational in 2025 and is capable of supporting the stable production and flexible ton-scale manufacturing of multiple high-value small-molecule raw materials.

This financing round will further support the commercialization of the company’s core product pipelines and strengthen its capabilities and market competitiveness in large-scale green biomanufacturing.